Isolated adrenocorticotrophic hormone deficiency in a patient treated with checkpoint inhibitor therapy

Azaan Ramani; Taylor Maloney; Brooke Mills; Samir Mazharuddin; Robert G. Mennel

doi:10.1080/08998280.2019.1698217

Isolated adrenocorticotrophic hormone deficiency in a patient treated with checkpoint inhibitor therapy

Azaan Ramani, Taylor Maloney, Brooke Mills, Samir Mazharuddin, Robert G. Mennel

Research output: Contribution to journal › Article › peer-review

Abstract

Treatment of advanced melanoma has significantly improved with the advent of checkpoint inhibitor therapy. With the widespread use of these agents, side effects are being increasingly recognized, including immune-related adverse events. We report the onset of adrenal insufficiency in a patient with advanced melanoma who was exposed to two checkpoint inhibitors: ipilimumab and nivolumab. His symptoms initially resolved with steroid replacement but he was unable to be weaned off hormone replacement and required long-term oral hydrocortisone treatment.

Original language	English (US)
Pages (from-to)	251-253
Number of pages	3
Journal	Baylor University Medical Center Proceedings
Volume	33
Issue number	2
DOIs	https://doi.org/10.1080/08998280.2019.1698217
State	Published - Apr 2 2020
Externally published	Yes

Keywords

Adrenal insufficiency
checkpoint inhibitor
cytotoxic T-lymphocyte antigen–4
hypophysitis
immune-related adverse events
ipilimumab
nivolumab
programmed death–1

ASJC Scopus subject areas

General Medicine

Access to Document

10.1080/08998280.2019.1698217

Cite this

@article{fd6798fbad57441b9bd9f32126ff6bc8,

title = "Isolated adrenocorticotrophic hormone deficiency in a patient treated with checkpoint inhibitor therapy",

abstract = "Treatment of advanced melanoma has significantly improved with the advent of checkpoint inhibitor therapy. With the widespread use of these agents, side effects are being increasingly recognized, including immune-related adverse events. We report the onset of adrenal insufficiency in a patient with advanced melanoma who was exposed to two checkpoint inhibitors: ipilimumab and nivolumab. His symptoms initially resolved with steroid replacement but he was unable to be weaned off hormone replacement and required long-term oral hydrocortisone treatment.",

keywords = "Adrenal insufficiency, checkpoint inhibitor, cytotoxic T-lymphocyte antigen–4, hypophysitis, immune-related adverse events, ipilimumab, nivolumab, programmed death–1",

author = "Azaan Ramani and Taylor Maloney and Brooke Mills and Samir Mazharuddin and Mennel, {Robert G.}",

note = "Publisher Copyright: {\textcopyright} 2019, Copyright {\textcopyright} 2019 Baylor University Medical Center.",

year = "2020",

month = apr,

day = "2",

doi = "10.1080/08998280.2019.1698217",

language = "English (US)",

volume = "33",

pages = "251--253",

journal = "Baylor University Medical Center Proceedings",

issn = "0899-8280",

publisher = "Taylor and Francis Ltd.",

number = "2",

}

TY - JOUR

T1 - Isolated adrenocorticotrophic hormone deficiency in a patient treated with checkpoint inhibitor therapy

AU - Ramani, Azaan

AU - Maloney, Taylor

AU - Mills, Brooke

AU - Mazharuddin, Samir

AU - Mennel, Robert G.

PY - 2020/4/2

Y1 - 2020/4/2

N2 - Treatment of advanced melanoma has significantly improved with the advent of checkpoint inhibitor therapy. With the widespread use of these agents, side effects are being increasingly recognized, including immune-related adverse events. We report the onset of adrenal insufficiency in a patient with advanced melanoma who was exposed to two checkpoint inhibitors: ipilimumab and nivolumab. His symptoms initially resolved with steroid replacement but he was unable to be weaned off hormone replacement and required long-term oral hydrocortisone treatment.

AB - Treatment of advanced melanoma has significantly improved with the advent of checkpoint inhibitor therapy. With the widespread use of these agents, side effects are being increasingly recognized, including immune-related adverse events. We report the onset of adrenal insufficiency in a patient with advanced melanoma who was exposed to two checkpoint inhibitors: ipilimumab and nivolumab. His symptoms initially resolved with steroid replacement but he was unable to be weaned off hormone replacement and required long-term oral hydrocortisone treatment.

KW - Adrenal insufficiency

KW - checkpoint inhibitor

KW - cytotoxic T-lymphocyte antigen–4

KW - hypophysitis

KW - immune-related adverse events

KW - ipilimumab

KW - nivolumab

KW - programmed death–1

UR - http://www.scopus.com/inward/record.url?scp=85077056699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077056699&partnerID=8YFLogxK

U2 - 10.1080/08998280.2019.1698217

DO - 10.1080/08998280.2019.1698217

M3 - Article

C2 - 32313477

AN - SCOPUS:85077056699

SN - 0899-8280

VL - 33

SP - 251

EP - 253

JO - Baylor University Medical Center Proceedings

JF - Baylor University Medical Center Proceedings

IS - 2

ER -

Isolated adrenocorticotrophic hormone deficiency in a patient treated with checkpoint inhibitor therapy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this